Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula

被引:10
|
作者
Carano, Francesco [1 ]
Sarno, Stefania [2 ]
De Fanti, Sara [2 ]
Serventi, Patrizia [2 ,3 ]
Bini, Carla [1 ]
Luiselli, Donata [2 ]
Pelotti, Susi [1 ]
机构
[1] Univ Bologna, Inst Legal Med, Dept Med & Surg Sci, Bologna, Italy
[2] Univ Bologna, Dept Biol Geol & Environm Sci, Mol Anthropol Lab, Bologna, Italy
[3] Alma Mater Studiorum Univ Bologna, Dept Cultural Heritage, Ravenna, Italy
基金
欧洲研究理事会;
关键词
Pharmacogenetics; cytochrome-P450 (CYP) genes; Italian population; genetic variation; geographic structure; GENOTYPE; POLYMORPHISMS; VARIANTS; EXPRESSION; JAPANESE; ENZYMES; ALLELE; PCR;
D O I
10.1080/03014460.2017.1378368
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
Background: Environmental conditions and past migratory events may have shaped genetic heterogeneity of clinically relevant enzymes involved in the phase I metabolism of the most common therapeutic drugs.Aim: To investigate the genetic variability of CYP2D6, CYP2B6, CYP2C19 and CYP2C9 across the Italian Peninsula, by sampling only ancestrally and geographically homogeneous individuals from northern, central and southern Italy.Subjects and methods: A total of 25 SNPs were genotyped in 174 unrelated Italian individuals by means of multiplex PCR and minisequencing reactions. CYP2D6 genotypic data were used to predict phenotypes and the phylogenetic relationships among reconstructed haplotypes were represented by means of a Median Joining Network.Results: Pairwise Fisher Exact tests revealed significant differences between northern and southern Italy in the distribution of CYP2C19 genotypes, with the CYP2C19*2 allele appearing over-represented in northern Italy. Likewise, significant differences in the distribution of CYP2D6 genotypes (*4/*3, *4/*4 and *6/*4) responsible for the poor metabolizer phenotype were observed in northern with respect to both central and southern Italy.Conclusions: The north-south structuring pattern showed by CYP2D6 and CYP2C19 underline how a deeper knowledge of the geographic distribution of alleles may improve clinical practice and help to avoid hypothetical bias in drug trials.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [31] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [32] REVERSIBLE AND TIME-DEPENDENT INHIBITION (TDI) OF CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4 IN HUMAN HEPATOCYTE SUSPENSIONS BY MODEL INHIBITORS
    Zhang, J. George
    Thuy Ho
    Patel, Reena
    Trisdale, Sarah K.
    Creegan, Tim
    Stresser, David M.
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S57 - S58
  • [33] Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population
    Arvanitidis, Kostas
    Ragia, Georgia
    Iordanidou, Maria
    Kyriaki, Sofia
    Xanthi, Athanasia
    Tavridou, Anna
    Manolopoulos, Vangelis G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (04) : 419 - 426
  • [34] Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
    Semiz, Sabina
    Dujic, Tanja
    Ostanek, Barbara
    Prnjavorac, Besim
    Bego, Tamer
    Malenica, Maja
    Marc, Janja
    Causevic, Adlija
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2010, 10 (04) : 287 - 291
  • [35] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    M. I. Veiga
    S. Asimus
    P. E. Ferreira
    J. P. Martins
    I. Cavaco
    V. Ribeiro
    T. N. Hai
    M. G. Petzold
    A. Björkman
    M. Ashton
    J. P. Gil
    European Journal of Clinical Pharmacology, 2009, 65 : 355 - 363
  • [36] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    Veiga, M. I.
    Asimus, S.
    Ferreira, P. E.
    Martins, J. P.
    Cavaco, I.
    Ribeiro, V.
    Hai, T. N.
    Petzold, M. G.
    Bjorkman, A.
    Ashton, M.
    Gil, J. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 355 - 363
  • [37] Efficiency to detect PM of CYP2D6, CYP2C9, and CYP2C19 based on volunteers' phenotype and genotype.
    Masson, E
    Tassé, C
    Larouche, R
    Girard, B
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P40 - P40
  • [38] REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9
    GUENTERT, TW
    GRAM, LF
    GRANGE, S
    BROSEN, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 137 - 137
  • [39] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [40] MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY
    GRAM, LF
    GUENTERT, TW
    GRANGE, S
    VISTISEN, K
    BROSEN, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) : 670 - 677